Essentials of Pharmacoeconomics and Outcomes Research: Application to Patient Care

1483 days ago, 842 views
PowerPoint PPT Presentation
Nuts and bolts of Pharmacoeconomics and Results Research: Application to Patient Consideration. Sara Shull PharmD, MBA. Sneak peak . Financial ideas Information sorts and sources Sorts of pharmacoeconomic examinations Point of view Cost-viability and incremental investigation Affectability examination

Presentation Transcript

Slide 1

Essentials of Pharmacoeconomics and Outcomes Research: Application to Patient Care Sara Shull PharmD, MBA

Slide 2

Preview Economic ideas Data sorts & sources Types of pharmacoeconomic investigations Perspective Cost-adequacy and incremental examination Sensitivity investigation Steps to pharmacoeconomic writing assessment Case contemplates for clinical practice and arrangement building

Slide 3

Opportunity Cost Time and cash as assets must be spent once – decision is unavoidable. O.C. is characterized as the sum that an asset could acquire in its most elevated esteemed option utilize. How would you contribute your time? Why set aside significant opportunity to find out about pharmacoeconomics and results look into?

Slide 4

How Can PE and Outcomes Enhance My Practice? PE is a guide to basic leadership with solid potential to: Mitigate the impact of marketing Puts specialist in the driver's seat Help set practice needs Enhances position of expert from payer's point of view Medicare arrangements to abatement pay-out to stem tide of spending shortage Private payers effectively are creating quality "report cards"

Slide 5

How Can PE and Outcomes Enhance My Practice? Measurably more inclined to be in charge of better achievement in clinical care by wiping out poor/superfluous care Ethical structure Fidelity to individual patients & stewardship to the general population great

Slide 6

Economics is: The investigation of how people & society wind up picking, with or without the utilization of cash, to utilize rare assets that could have elective uses, to create different products & disseminate them for utilization now, now or later on, among different individuals and gatherings in the public arena. Paul Samuelson

Slide 7

Pharmacoeconomics and Outcomes Research Using information to recognize your practice Data about viability clinical and humanistic Data about cost resources expended to accomplish efficacy endpoints (speculation)

Slide 8

Efficacy Data Management of adequacy endpoints in light of confirmation empowers clinicians to amplify endorsing abilities Evidence-based medicinal services is an assurance of the blend of those administrations, medicate items, and strategies that expand benefits and lessen dangers.

Slide 9

Cost Data Management of asset utilization empowers patients to expand obtaining power-Individual level-overseeing protection co-installments Group level-overseeing protection premiums crosswise over gatherings and boosting the quantity of guaranteed patients Govt level-maintaining open projects

Slide 10

Value Is the Goal of Practice Minimizing the proportion of cost to viability makes esteem best quantifiable profit Enhances your capacity to convey an unrivaled item

Slide 11

Basic Value of Medical Care Evidenced by general patterns: Increased utilization of medicinal care and doctor prescribed medications Mortality rates of specific infections have altogether declined Mean length of doctor's facility stay has likewise declined Despite this general proof, couple of particular information in regards to the genuine expenses and advantages ascribed to medications and therapeutic treatments exist

Slide 12

Objectives of pharmacoeconomics and results inquire about must start inside three measurements when considering results and estimation of health awareness Acceptable clinical results Acceptable humanistic results Acceptable monetary results

Slide 13

Types of Pharmacoeconomic Analysis

Slide 14

Common Misconceptions When Applying Pharmacoeconomic Principles Cost-viable care is at first the least expensive option in a way like different speculations, minimum cost choice may prompt to more prominent costs downstream Cost-viable care is result that creates "greatest" impact in a way to comparable ventures, littler augmentations of result might be accomplished at a lower general cost

Slide 15

Perspective The "perspective" considered in financial examinations impacts the results and costs thought to be most important: Provider Patient Payer Society

Slide 16

Comprehensive Definition of Cost-adequacy A treatment is esteemed to be a savvy methodology when the result is justified regardless of the cost in respect to contending choices. At the end of the day, rare assets are used to get the best an incentive available.

Slide 17

Average Cost-viability Specifies the cost of an operator required to accomplish every unit of impact. No correlation is made to option specialists. Normal cost-viability Cost of medication Resulting impact = Cost per unit of impact accomplished

Slide 18

Average Cost-adequacy Average cost-adequacy of Agent A $50.00 50 units of impact = $1.00 per unit Average cost-adequacy of Agent B $150.00 90 units of impact = $1.60 per unit

Slide 19

Incremental Cost-adequacy Analysis Makes correlations with other remedial choices, standard of care, or "doing nothing" (fake treatment) Fundamental proportion Cost choice B – Cost choice A Effect choice B – Effect choice A = Cost to accomplish one unit of impact

Slide 20

Incremental Cost Analysis

Slide 21

Incremental Effect Analysis

Slide 22

Comprehensive Incremental Cost-adequacy $150 - $50 $100 90 – 50 units = 40 units = $2.50 per unit of impact accomplished Therefore, on the grounds that Agent An is an accessible option with a lower normal cost for each unit of impact accomplished, the cost-adequacy of utilizing Agent B is lessened. The cost of Agent B is not in accordance with the item it conveys a poor esteem.

Slide 23

Grid Representing All Possible Relationships of Cost to Effect Between Two Competing Alternatives

Slide 24

Measuring Efficacy Data Variables What item (impact) can be reliably anticipated from utilization of medication or wellbeing administration? Generally decided from clinical trials Seek guide relationship to dreariness and mortality Survival/demise Myocardial localized necrosis avoided May depend on surrogate most likely identified with ultimate result to improve possibility of investigation Hemoglobin changes LDL cholesterol changes Intimal vessel divider thickness changes Randomized controlled clinical trial is highest quality level for determining viability information

Slide 25

Measuring Cost Data Variables What assets are expended to deliver one unit of the impact? Coordinate expenses drug item securing costs drug arrangement & organization costs drug checking costs treatment expenses of unfriendly impacts Indirect costs example of establishment circuitous cost

Slide 26

Discounting Costs to reach most legitimate determination about expenses produced after some time to accomplish an impact later on, it is important to consider that there is a period inclination related with cash Time-estimation of cash change Money close by is worth more than a similar sum at some point later on (we get a kick out of the chance to be paid as quickly as time permits, yet want to pay ultimately) Therefore future costs must be conformed to reflect introduce esteem. A $1000 cost one year from now requires just $930.00 close by today expecting a 7% rate of profitability.

Slide 27

Sensitivity Analysis Conclusions drawn from a monetary investigation may change, contingent upon the vulnerability of cost and impacts considered. S.A., by changing imperative factors & then recalculating outcomes, tests the legitimacy of decisions: Would Agent A still be most savvy if the impact of Agent B was more prominent than measured in clinical trial? Would Agent A still be most financially savvy if the observing expenses of Agent B were really lower? S.A. turns out to be progressively imperative as suppositions are made to a more noteworthy degree.

Slide 28

Steps to Pharmacoeconomic Literature Evaluation Evaluate: The nature of the diary Qualifications of creators Title and dynamic fair-minded? Contemplate strategy Perspective, examine plan, results and suitable choices, costs and fitting reducing, affectability investigation, & information sources Sponsorship-could inclination be presented? Incremental outcomes What is the conclusion and does it contrast between subgroups? What amount does stipend for instability change conclusion? Vogengerg, FR supervisor. Prologue to Applied Pharmacoeconomics, 2001

Slide 29

Cases for Development Formulary basic leadership (approach) Appropriate place for eplerenone (Inspra ® ) and spironolactone (bland) on Inpatient model of tertiary care scholarly restorative focus Clinical basic leadership for intense treatment (bedside) Choosing between low sub-atomic weight heparin or unfractionated heparin for the treatment of intense proximal profound vein thrombosis Clinical basic leadership for ceaseless treatment (bedside) Choosing between specific cyclooxygenase inhibitor and conventional non-steroidal mitigating specialist for administration of osteoarthritis agony Other proposals?

Slide 30

Treatment of Pain Resulting from Osteoarthritis Pain brings about noteworthy handicap and asset use influences 15% of US populace brings about > 100,000 hospitalizations every year NSAIDs successful agony alleviation 24 – 30% the cost of Cox-II inhibitors related with a huge danger of antagonistic impacts Dyspeptic manifestations More genuine non-dyspeptic impacts symptomatic ulcers, ulcer discharge, ulcer perforation Cox-II inhibitors compelling torment help generously more costly than NSAIDs related with lower danger of GI reactions

Slide 31

How would it be a good idea for me to treat my patient? NSAIDs are modest contrasted with Cox-II inhibitor: But won't the more costly specialist pay for itself many circumstances over by keeping a costly GI seep in my patient? Dyspeptic side effects are diminished by 15% Clinically critical ulcer complexities are decreased by half

Slide 32

Risk of GI drain: How Much Can It Be Altered? Not all osteoarthritis patients have an equivalent danger of building up a GI drain Is paying additional for GI insurance advocated in all patients? What amount can the danger of GI drain be adjusted by utilizing a Cox-II inhibitor rather than a NSAID? W